[go: up one dir, main page]

MX2018014135A - Tratamiento del dolor. - Google Patents

Tratamiento del dolor.

Info

Publication number
MX2018014135A
MX2018014135A MX2018014135A MX2018014135A MX2018014135A MX 2018014135 A MX2018014135 A MX 2018014135A MX 2018014135 A MX2018014135 A MX 2018014135A MX 2018014135 A MX2018014135 A MX 2018014135A MX 2018014135 A MX2018014135 A MX 2018014135A
Authority
MX
Mexico
Prior art keywords
pain
treatment
compounds
par2
signaling
Prior art date
Application number
MX2018014135A
Other languages
English (en)
Other versions
MX395658B (es
Inventor
Bunnett Nigel
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901912A external-priority patent/AU2016901912A0/en
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2018014135A publication Critical patent/MX2018014135A/es
Publication of MX395658B publication Critical patent/MX395658B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con compuestos y sus usos. En particular, con compuestos que inhiben la señalización del receptor 2 activado por proteasa endosomal (PAR2) y su uso en el tratamiento del dolor.
MX2018014135A 2016-05-20 2017-05-19 Tratamiento del dolor MX395658B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016901912A AU2016901912A0 (en) 2016-05-20 Treatment of Pain
PCT/AU2017/050469 WO2017197463A1 (en) 2016-05-20 2017-05-19 Treatment of pain

Publications (2)

Publication Number Publication Date
MX2018014135A true MX2018014135A (es) 2019-06-17
MX395658B MX395658B (es) 2025-03-26

Family

ID=60324618

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018014135A MX395658B (es) 2016-05-20 2017-05-19 Tratamiento del dolor
MX2022011564A MX2022011564A (es) 2016-05-20 2018-11-16 Tratamiento del dolor.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011564A MX2022011564A (es) 2016-05-20 2018-11-16 Tratamiento del dolor.

Country Status (9)

Country Link
US (1) US20190298743A1 (es)
EP (1) EP3458062A4 (es)
JP (3) JP2019516734A (es)
CN (1) CN109152777A (es)
AU (3) AU2017268039A1 (es)
CA (1) CA3024719A1 (es)
EA (1) EA201892672A1 (es)
MX (2) MX395658B (es)
WO (1) WO2017197463A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111698991A (zh) * 2017-12-20 2020-09-22 武田药品工业株式会社 蛋白酶激活受体-2的抑制剂
US20240066027A1 (en) 2020-12-03 2024-02-29 Domain Therapeutics Novel par-2 inhibitors
AU2023279857A1 (en) 2022-06-03 2024-11-14 Domain Therapeutics Novel par-2 inhibitors
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
US7541156B1 (en) * 2000-03-01 2009-06-02 Pasricha Pankaj J Method of identifying antinociceptive compounds using protease activated receptor-2
EP1691800A4 (en) * 2003-11-21 2009-03-18 Univ Newcastle Res Ass METHOD AND MEANS FOR INHIBITING DYNAMINE DEPENDENT ENDOCYTOSIS
CN1938013A (zh) * 2003-11-21 2007-03-28 纽卡斯尔大学研究协会有限公司 抑制发动蛋白依赖性的细胞内摄作用的方法和药剂
JP4896870B2 (ja) * 2004-04-08 2012-03-14 ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞膜ラフトと相互作用する構造を含む三者複合体およびその使用
CA2562266A1 (en) * 2004-04-08 2005-10-20 Jadolabs Gmbh Tripartite conjugates containing a structure interacting with cell membrane rafts and their use
WO2009034464A2 (en) * 2007-09-12 2009-03-19 Newcastle Innovation Limited Indole related compounds with physiological activity
AR070911A1 (es) * 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
WO2013010218A1 (en) * 2011-07-15 2013-01-24 Freie Universität Berlin Inhibition of clathrin
EP3049418A1 (en) * 2013-09-25 2016-08-03 Vertex Pharmaceuticals Incorporated Imidazopyridazines useful as inhibitors of the par-2 signaling pathway
EA201891472A1 (ru) * 2015-12-22 2018-12-28 Такеда Фармасьютикал Компани Лимитед Тройные модуляторы эндосомальных рецепторов, сопряженных с g-белком
AT518095B1 (de) * 2015-12-30 2018-01-15 Univ Wien Tech Verfahren zur Herstellung von ionischen Flüssigkeiten auf Basis des Bistriflimid-Anions
CN111698991A (zh) * 2017-12-20 2020-09-22 武田药品工业株式会社 蛋白酶激活受体-2的抑制剂

Also Published As

Publication number Publication date
AU2017268039A1 (en) 2018-12-06
AU2023201732A1 (en) 2023-04-20
CA3024719A1 (en) 2017-11-23
MX395658B (es) 2025-03-26
EP3458062A4 (en) 2020-01-15
JP7441246B2 (ja) 2024-02-29
MX2022011564A (es) 2023-06-15
CN109152777A (zh) 2019-01-04
EA201892672A1 (ru) 2019-04-30
JP2022061998A (ja) 2022-04-19
JP2019516734A (ja) 2019-06-20
WO2017197463A1 (en) 2017-11-23
US20190298743A1 (en) 2019-10-03
NZ788380A (en) 2025-07-25
AU2025202933A1 (en) 2025-05-15
JP2024073450A (ja) 2024-05-29
NZ748579A (en) 2025-07-25
EP3458062A1 (en) 2019-03-27

Similar Documents

Publication Publication Date Title
UY37341A (es) Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2019003398A1 (es) Inhibidores pirazólicos de magl.
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
MX386752B (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX377877B (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
CL2020001990A1 (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos. (hna. 1991-20)
MX378273B (es) Compuestos activos hacia bromodominios.
MX2020008107A (es) Moduladores del receptor nmda espiro-lactama y usos de los mismos.
MX2018014135A (es) Tratamiento del dolor.
CL2019001329A1 (es) Composiciones farmacéuticas moduladoras del receptor 7 de 5-hidroxitritpina y métodos de uso.
MX2021003110A (es) Agonistas del receptor x farnesoide y usos de los mismos.
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
ECSP18060875A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
GT201700194A (es) Formulación de combinación de tesofensina y betabloqueante
BR112018000217A2 (pt) sistemas de distribuição de nanopartículas aperfeiçoados
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
MX2017015292A (es) Composicion para tratar lesiones cerebrales.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina